ArticleClinical case reports2016
Olmesartan-induced enteropathy associated with cutaneous lesions.
Article in Clinical case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- A Rare Case of Olmesartan-Associated Enteropathy Successfully Managed With Steroid Taper.Cureus · 2023Article
- Olmesartan-Induced Enteropathy: A Case Report.Cureus · 2023Article
- Cutaneous ulcers in association with sprue-like enteropathy secondary to Losartan.Clinical case reports · 2021Article
- Severe Sprue-Like Enteropathy and Colitis due to Olmesartan: Lessons Learned From a Rare Entity.Gastroenterology research · 2020Article
- Pharmacy and therapeutics committees strategy to address olmesartan safety issues at a primary care level.International journal of clinical pharmacy · 2020Observational
- Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case Report.Current drug safety · 2019Article
- Rare Case of Olmesartan Induced Enteropathy.Spartan medical research journal · 2017Article
- Management of Hypertension Using Olmesartan Alone or in Combination.Cardiology and therapy · 2017Review
- Olmesartan-induced enteropathy associated with cutaneous lesions.Clinical case reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olmesartan is an angiotensin II receptor antagonist which may cause severe sprue-like enteropathy with duodenal villous atrophy. Skin lesions may be associated as reported for the first time in our case. Clinicians should be informed of this side effect and its reversibility after suspension of the drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.